| | By Angus Liu Eli Lilly quietly registered a new phase 3b trial pitting its Mounjaro against Novo Nordisk’s weight loss drug Wegovy in overweight or obese patients, teeing up an epic fight in a multibillion-dollar market. |
|
|
|
By Nick Paul Taylor Novartis has undertaken an old-fashioned decimation of its pipeline. The Swiss drugmaker has decided to dump or out-license 10% of its R&D projects to narrow its sights on five core therapeutic areas and focus investment on its most promising programs within those spaces. |
By Kevin Dunleavy As its Kenvue spinoff nears, J&J is conducting an IPO roadshow this week to drum up interest from investors, sources told The Wall Street Journal. They also said J&J hopes to raise at least $3.5 billion in the offering at a valuation of $40 billion. |
By Annalee Armstrong Long known as a neuroscience company, Biogen “could migrate” into immunology, CEO Christopher Viehbacher signaled Tuesday. |
|
Tuesday, May 2, 2023 | 11am ET / 8am PT In this webinar, we will discuss how tech-enabled traceability enables digitalization beyond tracking and tracing pharma drugs through the supply chain by leveraging Industry 4.0-equipped operations. Register now. 
|
|
By Angus Liu In a surprise announcement Wednesday, Bristol Myers Squibb said CEO Giovanni Caforio will end his eight-year tenure and hand the baton to chief commercialization officer Chris Boerner. |
By Gabrielle Masson Novartis is doling out $40 million cash for exclusive licensing rights to 3B Pharmaceuticals’ cancer-targeting tech, wrapping up some loose ends for a radiotherapy picked up from Clovis Oncology at the end of last year. |
By Sharon Klahr Coey Adults facing wet age-related macular degeneration and diabetic macular edema fear their world getting smaller, due to loss of eyesight. Roche’s Genentech addresses that issue head-on in its first DTC ad for Vabysmo. |
By Andrea Park Know Labs is one step closer to bringing its noninvasive glucose monitoring technology to the masses. |
By Angus Liu After a shortage prevented prostate cancer patients from getting Novartis’ Pluvicto, the FDA has quickly approved a radiotherapy manufacturing facility to help the company ramp up commercial supply. |
By Helen Floersh Preclinical success in primates could put a new gene therapy on the path to becoming the first-ever treatment for non-arteritic anterior ischemic optic neuropathy, along with many other aging diseases of the eye. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we're launching a mini-series on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
|
|---|
|
|
|
Tuesday, May 9, 2023 | 1pm ET / 10am PT Learn how a leading precision diagnostic testing company is partnering with an in-home care provider to accelerate and reduce the cost of clinical research. Hear about unique approaches in moving complex clinical trials and treatment into the home to create efficiencies and scale in patient recruitment, engagement, outcomes, and satisfaction. Register now. 
|
|
Research Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
Whitepaper Accelerated approval pathways create an additional layer of complexity in the chaotic oncology marketplace, leaving manufacturers of all sizes seeking a new commercialization model for launch success. Sponsored by: EVERSANA |
Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
Whitepaper This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
.png)
